Careers at Idrx

About Idrx

IDRx is a clinical-stage biopharmaceutical company focused on developing and commercializing precision therapeutics for cancer treatment. Founded in 2021, the company aims to address the limitations of current precision cancer medicines with highly potent and selective targeted therapies that tackle key tumor escape mechanisms, extending patients' response to therapy. IDRx's leading program, IDRX-42, is an oral small molecule KIT tyrosine kinase inhibitor in clinical development for gastrointestinal stromal tumors (GIST). These tumors are primarily driven by KIT gene mutations. The company is conducting clinical trials, including the StrateGIST 1 trial, to evaluate the effectiveness of IDRX-42 as a therapy for advanced GIST, and plans further trials to assess its use as a second-line therapy. IDRx is committed to transforming cancer care through intelligently designed precision therapeutics.